Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Our site is under planned maintenance. At this time, you will not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

The Quest for a COVID-19 Vaccine

WEBINAR

Only

The Quest for a COVID-19 Vaccine

Tuesday, February 2, 2021, 10:00 AM - Wednesday, February 3, 2021, 5:35 PM EST

Webinar

Presented By

 

The world is undergoing a global public health disaster unlike anything experienced since the 1918 influenza pandemic.  COVID-19 disease — which emerged from the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) — rapidly has spread from person to person across all borders.  With no “silver bullet” treatment currently available, the novel coronavirus pandemic has caused substantial morbidity and mortality worldwide.

Scientific researchers therefore have raced at an unprecedented pace to develop vaccines against SARS-CoV-2.  The importance of vaccines is two-fold: they prevent disease in the individual receiving the inoculation and the best vaccines are also able to block a pathogen’s transmission from person to person.  Academia, biotechnology, and government swiftly mobilized to develop candidate vaccines for SARS-CoV-2, several of which are now in use worldwide.  The field of vaccinology has demonstrated significant innovation in harnessing both traditional vaccine techniques and cutting-edge/not-yet-proven strategies as they seek to build an effective vaccine for SARS-CoV-2.  The sheer number of groups developing a vaccine, the diversity of candidate vaccines being explored, the range of technology platforms, and the enormous financial investment into these activities are all historic and hopefully will lead to additional efficacious licensed vaccines.  Despite recent successes, critical open questions and hurdles remain.

The world is waiting for more SARS-CoV-2 vaccines and hoping that multiple vaccines collectively will help control the current pandemic.  Moreover, the recent development a SARS-CoV-2 vaccine was the fastest in history.  This will open new innovation windows that we can learn from for the future.  This conference will provide a neutral forum to explore recent achievements and challenges in the development of a vaccine against SARS-CoV-2.  Through a series of keynote and plenary presentations, major themes to be considered for the program include:

  • the clinical epidemiology of COVID-19
  • the virology, immunology, and genetics of SARS-CoV-2,
  • efficacy data updates from candidate vaccines in Phase 3 trials,
  • updates from Phase 1 and 2 vaccine candidates,
  • COVID-19 vaccines in the elderly,
  • outbreak predictions, and
  • future considerations for the development and distribution of a COVID-19 vaccine

Registration

Member
$60
Nonmember Academia, Faculty, etc.
$130
Nonmember Corporate, Other
$170
Nonmember Not for Profit
$130
Nonmember Student, Undergrad, Grad, Fellow
$90
Member Student, Post-Doc, Fellow
$30

Keynote Speakers

Anthony S. Fauci
Anthony S. Fauci, MD

National Institute of Allergy and Infectious Diseases, NIH

Moncef Slaoui
Moncef Slaoui, PhD

Operation Warp Speed

Scientific Organizing Committee

Annaliesa Anderson, PhD
Annaliesa Anderson, PhD

Pfizer

Gregory Glenn, MD
Gregory Glenn, MD

Novavax

Emmanuel Hanon, PhD
Emmanuel Hanon, PhD

GlaxoSmithKline

Wayne Koff, PhD
Wayne Koff, PhD

Human Vaccines Project

Stanley Plotkin, MD
Stanley Plotkin, MD

University of Pennsylvania

Melanie Brickman Borchard, PhD, MSc
Melanie Brickman Borchard, PhD, MSc

New York Academy of Sciences

Speakers

Tal Zaks
Tal Zaks

Moderna

XueFeng Yu
XueFeng Yu, PhD

CanSino Biologics

Mark Woolhouse, FRSE FMedSci OBE
Mark Woolhouse, FRSE FMedSci OBE

The University of Edinburgh

Sean Tucker, PhD
Sean Tucker, PhD

Vaxart

Hanneke Schuitemaker, PhD
Hanneke Schuitemaker, PhD

Janssen Vaccines & Prevention B.V.

Melanie Saville, MD
Melanie Saville, MD

CEPI

Bali Pulendran, PhD
Bali Pulendran, PhD

Stanford University

Stanley Plotkin, MD
Stanley Plotkin, MD

University of Pennsylvania

Kevin Olival, PhD
Kevin Olival, PhD

EcoHealth Alliance

John Mascola, MD
John Mascola, MD

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH

Stefan O. Mueller, PhD
Stefan O. Mueller, PhD

CureVac

Thomas Lingelbach
Thomas Lingelbach

Valneva

Orin Levine, PhD
Orin Levine, PhD

Gates Foundation

Bette Korber
Bette Korber, PhD

Los Alamos National Laboratory

J. Joseph Kim, MBA, PhD
J. Joseph Kim, MBA, PhD

Inovio Pharmaceuticals

Kathrin Jansen, PhD
Kathrin Jansen, PhD

Pfizer

Sarah Gilbert, PhD
Sarah Gilbert, PhD

University of Oxford

Gregory Glenn, MD
Gregory Glenn, MD

Novavax

Shane Crotty, PhD
Shane Crotty, PhD

La Jolla Institute for Immunology

J. Robert Coleman, PhD, MBA
J. Robert Coleman, PhD, MBA

Codagenix

Nir Barzilai, MD
Nir Barzilai, MD

Albert Einstein College of Medicine

Ralph Baric, PhD
Ralph Baric, PhD

University of North Carolina

Annaliesa Anderson, PhD
Annaliesa Anderson, PhD

Pfizer

Peter Hotez, MD, PhD
Peter Hotez, MD, PhD

Baylor College of Medicine

Tuesday

February 02, 2021

10:00 AM

WELCOME REMARKS

Speaker

Melanie Brickman Borchard, PhD, MSc
New York Academy of Sciences
10:15 AM

KEYNOTE ADDRESS

Speakers

Moncef Slaoui, PhD
Operation Warp Speed
Keynote Chair: Stanley Plotkin, MD
University of Pennsylvania
11:00 AM

KEYNOTE ADDRESS: The Year in Review: A Vaccinologist’s Perspective

Speakers

Anthony S. Fauci, MD
National Institute of Allergy and Infectious Diseases (NIAID), NIH
Keynote Chair: Nicholas B. Dirks, PhD
New York Academy of Sciences
11:45 AM

Break

SESSION I: Epidemiology of COVID-19

Session Chairperson
Wayne Koff, PhD, Human Vaccines Project
12:05 PM

Tracking Changes in SARS-CoV-2 Spike

Speaker

Bette Korber, PhD
Los Alamos National Laboratory

SESSION II: Virology, Immunology, & Genetics of SARS-CoV-2

Session Chairperson
Gregory Glenn, MD, Novavax
12:35 PM

Virology of SARS-CoV-2

Speaker

Ralph Baric, PhD
University of North Carolina School of Medicine
1:05 PM

Immunology of SARS-CoV-2

Speaker

Shane Crotty, PhD
La Jolla Institute for Immunology
1:35 PM

Break

2:20 PM

Longitudinal Immune Profiling of Moderate and Severe COVID-19

Speaker

Bali Pulendran, PhD
Stanford University

SESSION III: Efficacy Studies, Part 1

Session Chairperson
Annaliesa Anderson, PhD, Pfizer
2:50 PM

Efficacy Data Updates from Moderna’s mRNA Vaccine Candidate

Speaker

Tal Zaks, MD, PhD
Moderna
3:20 PM

Efficacy Data Updates from the Pfizer-BioNTech mRNA Vaccine Candidate

Speaker

Kathrin Jansen, PhD
Pfizer
3:50 PM

Break

4:00 PM

Efficacy Data Updates from Novavax’s Protein-based Vaccine Candidate

Speaker

Gregory Glenn, MD
Novavax

SESSION IV: Update Talks

Session Chairperson
Emmanuel Hanon, PhD, GlaxoSmithKline
4:30 PM

Updates from Codagenix’s Vaccine Candidate

Speaker

J. Robert Coleman, PhD, MBA
Codagenix
4:50 PM

Development of DNA-Based COVID-19 Vaccine

Speaker

J. Joseph Kim, MBA, PhD
Inovio Pharmaceuticals

SESSION V: Day 1 Closing Talk

Session Chairperson
Stanley Plotkin, MD, University of Pennsylvania
5:10 PM

The Role of Modern Vaccinology in Responding to New Epidemics

Speaker

John R. Mascola, MD
National Institute of Allergy and Infectious Diseases, NIH
5:40 PM

Closing Remarks, Day 1

5:45 PM

End of Day

Wednesday

February 03, 2021

10:30 AM

WELCOME REMARKS

Speaker

Melanie Brickman Borchard, PhD, MSc
New York Academy of Sciences

SESSION VI: Efficacy Studies, Part 2

Session Chairperson
Gregory Glenn, MD, Novavax
10:35 AM

Update on ChAdOx1 nCoV-19/AZD1222

Speaker

Sarah Gilbert, PhD
University of Oxford
11:05 AM

Efficacy Data Updates from CanSino Biologics’ Viral-Vector Vaccine Candidate

Speaker

Xuefeng Yu, PhD, CanSino Biologics
11:35 AM

Break

11:45 AM

Janssen’s Effort in the Development of an Ad26 Based COVID-19 Vaccine

Speaker

Hanneke Schuitemaker, PhD
Janssen Vaccines & Prevention B.V. (Pharmaceutical companies of Johnson & Johnson)

SESSION VII: Update Talks

Session Chairperson
Emmanuel Hanon, PhD, GlaxoSmithKline
12:15 PM

Updates from Valneva's Inactivated, Adjuvanted COVID-19 Vaccine Candidate

Speaker

Thomas Lingelbach
Valneva
12:35 PM

Updates from CureVac’s Messenger RNA (mRNA)-based Covid-19 Vaccine Candidate

Speaker

Stefan O. Mueller, PhD
CureVac
12:55 PM

Low Cost Recombinant Protein COVID19 Vaccine for Global Health

Speaker

Peter Hotez, MD, PhD
Baylor College of Medicine
1:15 PM

Vaxart’s Oral Covid-19 Vaccine - Clinical Trial Update

Speaker

Sean Tucker, PhD
Vaxart
1:35 PM

Break

SESSION VIII: COVID-19 Vaccines in the Elderly

Session Chairperson
Annaliesa Anderson, PhD, Pfizer
2:15 PM

Immunosenescence and COVID-19 Vaccines for the Elderly

Speaker

Nir Barzilai, MD
Albert Einstein College of Medicine

SESSION IX: Outbreak Predictions

Session Chairperson
Wayne Koff, PhD, Human Vaccines Project
2:45 PM

How to Make Predictions about Future Infectious Disease Risks

Speaker

Mark Woolhouse, FRSE FMedSci OBE
The University of Edinburgh
3:15 PM

Challenges to Prediction and Prevention of the Next Pandemic Zoonosis

Speaker

Kevin Olival, PhD
EcoHealth Alliance

SESSION X: Future Considerations

Session Chairperson
Wayne Koff, PhD, Human Vaccines Project
3:45 PM

Progress in Novel Treatments for COVID-19 and Beyond

Speaker

Annaliesa Anderson, PhD
Pfizer
4:15 PM

Lessons Learned from COVID-19 Vaccine Development for Future Pandemic Preparedness

Speaker

Melanie Saville, MD
CEPI
4:45 PM

Access, Deployment, and Global Distribution Challenges for COVID-19 Vaccines

Speaker

Orin Levine, PhD
Gates Foundation
5:15 PM

The Plague Year of 2020 and Its Effect on Vaccinology

Speaker

Stanley Plotkin, MD
University of Pennsylvania
5:30 PM

Closing Remarks, Day 2

Speaker

Melanie Brickman Borchard, PhD, MSc
New York Academy of Sciences
5:40 PM

End of Conference

Loading...